Inhibition of the Platelet Glycoprotein IIb/IIIa Receptor with Tirofiban in Unstable Angina and Non–Q-Wave Myocardial Infarction
Platelet activation and aggregation, with resultant arterial thrombus formation, are pivotal in the pathophysiology of acute coronary syndromes. 1 , 2 The development of inhibitors of fibrinogen binding to the platelet glycoprotein IIb/IIIa receptor has expanded the therapeutic options for treating...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 1998-05, Vol.338 (21), p.1488-1497 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1497 |
|---|---|
| container_issue | 21 |
| container_start_page | 1488 |
| container_title | The New England journal of medicine |
| container_volume | 338 |
| creator | Bazzino, O Barrero, C Garre, L Sosa, A |
| description | Platelet activation and aggregation, with resultant arterial thrombus formation, are pivotal in the pathophysiology of acute coronary syndromes.
1
,
2
The development of inhibitors of fibrinogen binding to the platelet glycoprotein IIb/IIIa receptor has expanded the therapeutic options for treating thrombotic disorders.
3
,
4
The effectiveness of the inhibitor drugs in preventing acute ischemic complications related to abrupt vessel closure after angioplasty has been well documented.
5
–
9
Pilot studies have suggested that blockade of the platelet glycoprotein IIb/IIIa receptor may also be useful in the treatment of patients with unstable angina, whether or not they are also undergoing interventional procedures.
10
–
13
We . . . |
| doi_str_mv | 10.1056/NEJM199805213382102 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_223958642</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>29515688</sourcerecordid><originalsourceid>FETCH-LOGICAL-c528t-5821d0321f01c39ddea6700e18c01832546fcee78f34a824beee61235e6223563</originalsourceid><addsrcrecordid>eNp9kE1uFDEQhS0ECkPgBAjJQuxQE__22MsoCqFREn6UiGXL7S4zHnXbg-0BzQ5xBW7ISXA0o6wQtaha1Ff19B5Czyl5Q4lsT67P319RrRWRjHKuGCXsAVpQyXkjBGkfogUhTDViqflj9CTnNalFhT5CR1pqTQlfoF9dWPnBFx8Djg6XFeCPkykwQcEX087GTYoFfMBdN5x0XWfwZ7CwKTHhH76s8I1P0fnBBFyZ25CLGSbAp-GrDwabMOLrGP78_P2p-WK-A77aRWvS6M2Eu-BMsne6T9EjZ6YMzw7zGN2-Pb85e9dcfrjozk4vGyuZKo2sBkfCGXWEWq7HEUy7JASosoQqzqRonQVYKseFUUwMANBSxiW0rPaWH6OX-7_V0rct5NKv4zaFKtlXQEvVClYhvodsijkncP0m-dmkXU9Jf5d6_4_U69WLw-vtMMN4f3OIue5fHfYmWzO5ZIL1-R6r8kJpWbHXe2yecx9gPf9X9C-DkJYN</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>223958642</pqid></control><display><type>article</type><title>Inhibition of the Platelet Glycoprotein IIb/IIIa Receptor with Tirofiban in Unstable Angina and Non–Q-Wave Myocardial Infarction</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>New England Journal of Medicine</source><creator>Bazzino, O ; Barrero, C ; Garre, L ; Sosa, A</creator><creatorcontrib>Bazzino, O ; Barrero, C ; Garre, L ; Sosa, A ; The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators ; Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators</creatorcontrib><description>Platelet activation and aggregation, with resultant arterial thrombus formation, are pivotal in the pathophysiology of acute coronary syndromes.
1
,
2
The development of inhibitors of fibrinogen binding to the platelet glycoprotein IIb/IIIa receptor has expanded the therapeutic options for treating thrombotic disorders.
3
,
4
The effectiveness of the inhibitor drugs in preventing acute ischemic complications related to abrupt vessel closure after angioplasty has been well documented.
5
–
9
Pilot studies have suggested that blockade of the platelet glycoprotein IIb/IIIa receptor may also be useful in the treatment of patients with unstable angina, whether or not they are also undergoing interventional procedures.
10
–
13
We . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJM199805213382102</identifier><identifier>PMID: 9599103</identifier><identifier>CODEN: NEJMAG</identifier><language>eng</language><publisher>Boston, MA: Massachusetts Medical Society</publisher><subject>Acute coronary syndromes ; Aged ; Angina pectoris ; Angina, Unstable - drug therapy ; Angina, Unstable - mortality ; Antianginal agents. Coronary vasodilator agents ; Aspirin - therapeutic use ; Biological and medical sciences ; Blood clots ; Cardiovascular system ; Double-Blind Method ; Drug dosages ; Drug Therapy, Combination ; Female ; Fibrinolytic Agents - adverse effects ; Fibrinolytic Agents - therapeutic use ; Heart attacks ; Hemorrhage - chemically induced ; Heparin - adverse effects ; Heparin - therapeutic use ; Humans ; Incidence ; Male ; Medical sciences ; Middle Aged ; Myocardial Infarction - drug therapy ; Myocardial Infarction - mortality ; Myocardial Infarction - prevention & control ; Myocardial Ischemia - epidemiology ; Myocardial Ischemia - prevention & control ; Pharmacology. Drug treatments ; Platelet Aggregation Inhibitors - adverse effects ; Platelet Aggregation Inhibitors - therapeutic use ; Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors ; Proportional Hazards Models ; Tyrosine - adverse effects ; Tyrosine - analogs & derivatives ; Tyrosine - therapeutic use</subject><ispartof>The New England journal of medicine, 1998-05, Vol.338 (21), p.1488-1497</ispartof><rights>Copyright © 1998 Massachusetts Medical Society. All rights reserved.</rights><rights>1998 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c528t-5821d0321f01c39ddea6700e18c01832546fcee78f34a824beee61235e6223563</citedby><cites>FETCH-LOGICAL-c528t-5821d0321f01c39ddea6700e18c01832546fcee78f34a824beee61235e6223563</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJM199805213382102$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.nejm.org/doi/full/10.1056/NEJM199805213382102$$EHTML$$P50$$Gmms$$H</linktohtml><link.rule.ids>314,776,780,2746,2747,26082,27903,27904,52360,54042</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2234895$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9599103$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bazzino, O</creatorcontrib><creatorcontrib>Barrero, C</creatorcontrib><creatorcontrib>Garre, L</creatorcontrib><creatorcontrib>Sosa, A</creatorcontrib><creatorcontrib>The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators</creatorcontrib><creatorcontrib>Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators</creatorcontrib><title>Inhibition of the Platelet Glycoprotein IIb/IIIa Receptor with Tirofiban in Unstable Angina and Non–Q-Wave Myocardial Infarction</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>Platelet activation and aggregation, with resultant arterial thrombus formation, are pivotal in the pathophysiology of acute coronary syndromes.
1
,
2
The development of inhibitors of fibrinogen binding to the platelet glycoprotein IIb/IIIa receptor has expanded the therapeutic options for treating thrombotic disorders.
3
,
4
The effectiveness of the inhibitor drugs in preventing acute ischemic complications related to abrupt vessel closure after angioplasty has been well documented.
5
–
9
Pilot studies have suggested that blockade of the platelet glycoprotein IIb/IIIa receptor may also be useful in the treatment of patients with unstable angina, whether or not they are also undergoing interventional procedures.
10
–
13
We . . .</description><subject>Acute coronary syndromes</subject><subject>Aged</subject><subject>Angina pectoris</subject><subject>Angina, Unstable - drug therapy</subject><subject>Angina, Unstable - mortality</subject><subject>Antianginal agents. Coronary vasodilator agents</subject><subject>Aspirin - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Blood clots</subject><subject>Cardiovascular system</subject><subject>Double-Blind Method</subject><subject>Drug dosages</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>Fibrinolytic Agents - adverse effects</subject><subject>Fibrinolytic Agents - therapeutic use</subject><subject>Heart attacks</subject><subject>Hemorrhage - chemically induced</subject><subject>Heparin - adverse effects</subject><subject>Heparin - therapeutic use</subject><subject>Humans</subject><subject>Incidence</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Myocardial Infarction - drug therapy</subject><subject>Myocardial Infarction - mortality</subject><subject>Myocardial Infarction - prevention & control</subject><subject>Myocardial Ischemia - epidemiology</subject><subject>Myocardial Ischemia - prevention & control</subject><subject>Pharmacology. Drug treatments</subject><subject>Platelet Aggregation Inhibitors - adverse effects</subject><subject>Platelet Aggregation Inhibitors - therapeutic use</subject><subject>Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors</subject><subject>Proportional Hazards Models</subject><subject>Tyrosine - adverse effects</subject><subject>Tyrosine - analogs & derivatives</subject><subject>Tyrosine - therapeutic use</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kE1uFDEQhS0ECkPgBAjJQuxQE__22MsoCqFREn6UiGXL7S4zHnXbg-0BzQ5xBW7ISXA0o6wQtaha1Ff19B5Czyl5Q4lsT67P319RrRWRjHKuGCXsAVpQyXkjBGkfogUhTDViqflj9CTnNalFhT5CR1pqTQlfoF9dWPnBFx8Djg6XFeCPkykwQcEX087GTYoFfMBdN5x0XWfwZ7CwKTHhH76s8I1P0fnBBFyZ25CLGSbAp-GrDwabMOLrGP78_P2p-WK-A77aRWvS6M2Eu-BMsne6T9EjZ6YMzw7zGN2-Pb85e9dcfrjozk4vGyuZKo2sBkfCGXWEWq7HEUy7JASosoQqzqRonQVYKseFUUwMANBSxiW0rPaWH6OX-7_V0rct5NKv4zaFKtlXQEvVClYhvodsijkncP0m-dmkXU9Jf5d6_4_U69WLw-vtMMN4f3OIue5fHfYmWzO5ZIL1-R6r8kJpWbHXe2yecx9gPf9X9C-DkJYN</recordid><startdate>19980521</startdate><enddate>19980521</enddate><creator>Bazzino, O</creator><creator>Barrero, C</creator><creator>Garre, L</creator><creator>Sosa, A</creator><general>Massachusetts Medical Society</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope></search><sort><creationdate>19980521</creationdate><title>Inhibition of the Platelet Glycoprotein IIb/IIIa Receptor with Tirofiban in Unstable Angina and Non–Q-Wave Myocardial Infarction</title><author>Bazzino, O ; Barrero, C ; Garre, L ; Sosa, A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c528t-5821d0321f01c39ddea6700e18c01832546fcee78f34a824beee61235e6223563</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Acute coronary syndromes</topic><topic>Aged</topic><topic>Angina pectoris</topic><topic>Angina, Unstable - drug therapy</topic><topic>Angina, Unstable - mortality</topic><topic>Antianginal agents. Coronary vasodilator agents</topic><topic>Aspirin - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Blood clots</topic><topic>Cardiovascular system</topic><topic>Double-Blind Method</topic><topic>Drug dosages</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>Fibrinolytic Agents - adverse effects</topic><topic>Fibrinolytic Agents - therapeutic use</topic><topic>Heart attacks</topic><topic>Hemorrhage - chemically induced</topic><topic>Heparin - adverse effects</topic><topic>Heparin - therapeutic use</topic><topic>Humans</topic><topic>Incidence</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Myocardial Infarction - drug therapy</topic><topic>Myocardial Infarction - mortality</topic><topic>Myocardial Infarction - prevention & control</topic><topic>Myocardial Ischemia - epidemiology</topic><topic>Myocardial Ischemia - prevention & control</topic><topic>Pharmacology. Drug treatments</topic><topic>Platelet Aggregation Inhibitors - adverse effects</topic><topic>Platelet Aggregation Inhibitors - therapeutic use</topic><topic>Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors</topic><topic>Proportional Hazards Models</topic><topic>Tyrosine - adverse effects</topic><topic>Tyrosine - analogs & derivatives</topic><topic>Tyrosine - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bazzino, O</creatorcontrib><creatorcontrib>Barrero, C</creatorcontrib><creatorcontrib>Garre, L</creatorcontrib><creatorcontrib>Sosa, A</creatorcontrib><creatorcontrib>The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators</creatorcontrib><creatorcontrib>Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bazzino, O</au><au>Barrero, C</au><au>Garre, L</au><au>Sosa, A</au><aucorp>The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators</aucorp><aucorp>Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Inhibition of the Platelet Glycoprotein IIb/IIIa Receptor with Tirofiban in Unstable Angina and Non–Q-Wave Myocardial Infarction</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>1998-05-21</date><risdate>1998</risdate><volume>338</volume><issue>21</issue><spage>1488</spage><epage>1497</epage><pages>1488-1497</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><coden>NEJMAG</coden><abstract>Platelet activation and aggregation, with resultant arterial thrombus formation, are pivotal in the pathophysiology of acute coronary syndromes.
1
,
2
The development of inhibitors of fibrinogen binding to the platelet glycoprotein IIb/IIIa receptor has expanded the therapeutic options for treating thrombotic disorders.
3
,
4
The effectiveness of the inhibitor drugs in preventing acute ischemic complications related to abrupt vessel closure after angioplasty has been well documented.
5
–
9
Pilot studies have suggested that blockade of the platelet glycoprotein IIb/IIIa receptor may also be useful in the treatment of patients with unstable angina, whether or not they are also undergoing interventional procedures.
10
–
13
We . . .</abstract><cop>Boston, MA</cop><pub>Massachusetts Medical Society</pub><pmid>9599103</pmid><doi>10.1056/NEJM199805213382102</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 1998-05, Vol.338 (21), p.1488-1497 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_journals_223958642 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; New England Journal of Medicine |
| subjects | Acute coronary syndromes Aged Angina pectoris Angina, Unstable - drug therapy Angina, Unstable - mortality Antianginal agents. Coronary vasodilator agents Aspirin - therapeutic use Biological and medical sciences Blood clots Cardiovascular system Double-Blind Method Drug dosages Drug Therapy, Combination Female Fibrinolytic Agents - adverse effects Fibrinolytic Agents - therapeutic use Heart attacks Hemorrhage - chemically induced Heparin - adverse effects Heparin - therapeutic use Humans Incidence Male Medical sciences Middle Aged Myocardial Infarction - drug therapy Myocardial Infarction - mortality Myocardial Infarction - prevention & control Myocardial Ischemia - epidemiology Myocardial Ischemia - prevention & control Pharmacology. Drug treatments Platelet Aggregation Inhibitors - adverse effects Platelet Aggregation Inhibitors - therapeutic use Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors Proportional Hazards Models Tyrosine - adverse effects Tyrosine - analogs & derivatives Tyrosine - therapeutic use |
| title | Inhibition of the Platelet Glycoprotein IIb/IIIa Receptor with Tirofiban in Unstable Angina and Non–Q-Wave Myocardial Infarction |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T04%3A02%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Inhibition%20of%20the%20Platelet%20Glycoprotein%20IIb/IIIa%20Receptor%20with%20Tirofiban%20in%20Unstable%20Angina%20and%20Non%E2%80%93Q-Wave%20Myocardial%20Infarction&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Bazzino,%20O&rft.aucorp=The%20Platelet%20Receptor%20Inhibition%20in%20Ischemic%20Syndrome%20Management%20in%20Patients%20Limited%20by%20Unstable%20Signs%20and%20Symptoms%20(PRISM-PLUS)%20Study%20Investigators&rft.date=1998-05-21&rft.volume=338&rft.issue=21&rft.spage=1488&rft.epage=1497&rft.pages=1488-1497&rft.issn=0028-4793&rft.eissn=1533-4406&rft.coden=NEJMAG&rft_id=info:doi/10.1056/NEJM199805213382102&rft_dat=%3Cproquest_cross%3E29515688%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=223958642&rft_id=info:pmid/9599103&rfr_iscdi=true |